EB-0156
EB-0156 is a potent inhibitor of ER α-glucosidases (α-Glu) Iand II with IC50s of 0.0479 and less than 0.001 μM, respectively. EB-0156 is a N-substituted derivative of valiolamine with broad-spectrum antiviral. EB-0156 has the potential for the reseach of broad-spectrum agent against the existing and emerging viruses.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2832824-43-6
- Formule: C21H32N6O7
- Masse moléculaire:480.51
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
Glucosidase[1]
Endoplasmic Reticulum α-Glucosidases I and II inhibitor[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Vero | CC50 |
125.5 μM
Compound: EB-0156
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 3 to 5 days by Cell titer-glo luminescent assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 3 to 5 days by Cell titer-glo luminescent assay
|
[PMID: 34870992] |
Chemical Information
-
CAS No. 2832824-43-6
-
Masse moléculaire 480.51
-
Formule C21H32N6O7
-
SMILES
O[C@@H]1[C@](O)(C[C@@H]([C@@H]([C@H]1O)O)NCCCCCCNC2=C(C=C(C=C2)N3N=CC=N3)[N+]([O-])=O)CO
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
EB-0156 Related Classifications
HY-145274 Related Classifications
Powered by Bioz